An anti-phospholipid Mab would take care of that part of the disease. Leronlimab causes a rapid enough decline in viral load that I don't think it would be necessary. It's quite likely that leronlimab's boosting of CD8+ T-cells allows the targeting of virus bearing tentacled cells that exude phosphatidylserine (the specific phospholipid). In normal immune reactions phosphatidylserine is used by cells to signal it to be attacked.